Prognostic utility of b-tubulin isotype III and correlations  with other molecular and clinicopathological variables in patients  with early breast cancer: a translational Hellenic Cooperative  Oncology Group (HeCOG) study

Prognostic utility of b-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : George Pentheroudakis Anna Batistatou Konstantine T. Kalogeras Ralf Kronenwett Ralph M. Wirtz Evangelos Bournakis Anastasia G. Eleftheraki
  • چاپ و سال / کشور: 2011

Description

We evaluated the prognostic and predictive utility of b-tubulin isotype III (TUBB3) tumour gene transcription in early breast cancer patients enrolled in a randomised study. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was applied for assessment of TUBB3, ER, PgR, HER2 and MAPT messenger RNA and immunohistochemistry (IHC) for protein expression in 314 patients enrolled in trial HE10/97, evaluating epirubicin–alkylator adjuvant chemotherapy with or without paclitaxel. High TUBB3 mRNA status was associated with advanced T stage, high histological grade, low mRNA and protein levels of ER, PgR and MAPT, and high levels of HER2 (p\0.001). At a median follow-up of 98 months, multivariate analysis showed high TUBB3 mRNA status to have prognostic significance for DFS (HR = 1.83, 95% CI 1.25–2.68, p = 0.002) and OS (HR = 1.71, 95% CI 1.03–2.83, p = 0.038), along with the number of involved axillary nodes, PgR mRNA status and tumour grade. TUBB3 mRNA levels did not predict benefit from inclusion of paclitaxel in adjuvant chemotherapy (test for interaction p = 0.96 for OS, p = 0.46 for DFS). Transcriptional activity of b-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy.
Breast Cancer Res Treat (2011) 127:179–193 DOI 10.1007/s10549-011-1427-0 Received: 31 October 2010 / Accepted: 25 February 2011 / Published online: 9 March 2011  Springer Science+Business Media, LLC. 2011
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری